EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction

Charu Sharma, Abubaker Suliman, Ali Mohammed Aldhaheri, Saeed Mohammed Alnuaimi, Khaled Mohamed Alderei, Sania Mazin AlHamad, Javed Yasin Pathan, Elhadi H Aburawi

Frontiers in Cardiovascular Medicine · 24.07.2026 · 13

DOI: 10.3389/fcvm.2026.1836882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 24.07.2026. Verfasst von Charu Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Endothelial dysfunction is an early and pivotal event in the development of cardiovascular disease and a key mechanism linked to atherosclerotic plaque formation. Endocan and endoglin are emerging cardiometabolic markers and novel endothelial mediators that promote vascular smooth muscle cell proliferation and migration, contributing to intima-media thickening.

Objectives

We aimed to assess endocan and soluble endoglin levels in young adults in the United Arab Emirates (UAE) and the associations among hyperglycemia, dyslipidemia, and endothelial dysfunction. Materials and methods In this cross-sectional case-control study at UAE University, 182 young adults aged 18–22 years were classified as normal body weight (BW) ( n = 61) or excess BW ( n = 121) based on their body mass index. Anthropometry, systolic and diastolic blood pressures (SBP and DBP), inflammatory markers, the lipid profile, HbA1c, and plasma endocan and endoglin were measured. Multivariable linear regression analysis was performed to determine the associations between endoglin and log-transformed endocan and BW status and cardiometabolic variables, adjusting for age, sex, and family history of type 2 diabetes mellitus and hypertension.

Results

Of the 182 participants, 88 (48%) were women, 121 (67%) had excess BW, and the mean (standard deviation) age was 19.96 years (1.79). Compared with the normal body weight group, the excess body weight group had significantly higher SBP, DBP, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor- α , interleukin-6, apolipoprotein B (Apo-B), and log-transformed endocan (all p ≤ 0.041), along with significantly lower high-density lipoprotein-cholesterol ( p = 0.021) and apolipoprotein A (Apo-A) ( p = 0.041) levels. In the adjusted models, endoglin was positively associated with excess BW, DBP, TC, and LDL-C, whereas log-transformed endocan was positively associated with excess BW, SBP, DBP, TC, LDL-C, Apo-B, and hs-CRP.

Conclusions

Among these young adults, elevated endocan and endoglin levels correlated with excess body weight and adverse metabolic profiles. Prospective studies are needed to determine whether these biomarkers predict future cardiometabolic or vascular outcomes.

Schlagwörter

Stichwörter der Autor:innen

cardiovascular diseaseendocanendoglinendothelial dysfunctioninflammatory markers

Autor:innen und Institutionen

  • Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
  • Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.

Zitieren

APA

Sharma, C., Suliman, A., Aldhaheri, A. M., Alnuaimi, S. M., Alderei, K. M., AlHamad, S. M., Pathan, J. Y., & Aburawi, E. H. (2026). Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1836882

Vancouver

Sharma C, Suliman A, Aldhaheri AM, Alnuaimi SM, Alderei KM, AlHamad SM, et al. Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1836882

BibTeX
@article{Sharma2026,
  author = {Sharma, Charu and Suliman, Abubaker and Aldhaheri, Ali Mohammed and Alnuaimi, Saeed Mohammed and Alderei, Khaled Mohamed and AlHamad, Sania Mazin and Pathan, Javed Yasin and Aburawi, Elhadi H},
  title = {Clinical relevance of circulating endocan and endoglin in excess body weight-associated endothelial dysfunction},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1836882}
}
Kostenlos starten →